|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ADPGK |
Gene summary for ADPGK |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ADPGK | Gene ID | 83440 |
| Gene name | ADP dependent glucokinase | |
| Gene Alias | 2610017G09Rik | |
| Cytomap | 15q24.1 | |
| Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | Q9BRR6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 83440 | ADPGK | LZE4T | Human | Esophagus | ESCC | 2.01e-09 | 2.02e-01 | 0.0811 |
| 83440 | ADPGK | LZE5T | Human | Esophagus | ESCC | 2.36e-06 | 2.66e-01 | 0.0514 |
| 83440 | ADPGK | LZE7T | Human | Esophagus | ESCC | 9.47e-07 | 3.80e-01 | 0.0667 |
| 83440 | ADPGK | LZE20T | Human | Esophagus | ESCC | 7.82e-05 | 1.33e-01 | 0.0662 |
| 83440 | ADPGK | LZE24T | Human | Esophagus | ESCC | 1.78e-15 | 2.58e-01 | 0.0596 |
| 83440 | ADPGK | LZE21T | Human | Esophagus | ESCC | 1.59e-03 | 1.57e-01 | 0.0655 |
| 83440 | ADPGK | P1T-E | Human | Esophagus | ESCC | 1.47e-07 | 3.18e-01 | 0.0875 |
| 83440 | ADPGK | P2T-E | Human | Esophagus | ESCC | 6.71e-25 | 3.91e-01 | 0.1177 |
| 83440 | ADPGK | P4T-E | Human | Esophagus | ESCC | 1.15e-32 | 6.71e-01 | 0.1323 |
| 83440 | ADPGK | P5T-E | Human | Esophagus | ESCC | 5.30e-09 | 1.16e-01 | 0.1327 |
| 83440 | ADPGK | P8T-E | Human | Esophagus | ESCC | 1.14e-32 | 4.50e-01 | 0.0889 |
| 83440 | ADPGK | P9T-E | Human | Esophagus | ESCC | 6.94e-22 | 3.98e-01 | 0.1131 |
| 83440 | ADPGK | P10T-E | Human | Esophagus | ESCC | 3.45e-42 | 6.01e-01 | 0.116 |
| 83440 | ADPGK | P11T-E | Human | Esophagus | ESCC | 1.08e-14 | 6.19e-01 | 0.1426 |
| 83440 | ADPGK | P12T-E | Human | Esophagus | ESCC | 1.72e-28 | 4.82e-01 | 0.1122 |
| 83440 | ADPGK | P15T-E | Human | Esophagus | ESCC | 5.63e-33 | 5.93e-01 | 0.1149 |
| 83440 | ADPGK | P16T-E | Human | Esophagus | ESCC | 5.52e-26 | 5.38e-01 | 0.1153 |
| 83440 | ADPGK | P17T-E | Human | Esophagus | ESCC | 7.92e-09 | 2.90e-01 | 0.1278 |
| 83440 | ADPGK | P19T-E | Human | Esophagus | ESCC | 2.97e-09 | 4.75e-01 | 0.1662 |
| 83440 | ADPGK | P20T-E | Human | Esophagus | ESCC | 3.10e-21 | 4.74e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006091110 | Esophagus | ESCC | generation of precursor metabolites and energy | 331/8552 | 490/18723 | 3.86e-23 | 8.45e-21 | 331 |
| GO:0046034111 | Esophagus | ESCC | ATP metabolic process | 189/8552 | 277/18723 | 1.99e-14 | 1.04e-12 | 189 |
| GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
| GO:0019693111 | Esophagus | ESCC | ribose phosphate metabolic process | 234/8552 | 396/18723 | 4.24e-08 | 7.76e-07 | 234 |
| GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
| GO:00059969 | Esophagus | ESCC | monosaccharide metabolic process | 159/8552 | 257/18723 | 1.11e-07 | 1.81e-06 | 159 |
| GO:00193189 | Esophagus | ESCC | hexose metabolic process | 147/8552 | 237/18723 | 2.63e-07 | 3.94e-06 | 147 |
| GO:0009259111 | Esophagus | ESCC | ribonucleotide metabolic process | 224/8552 | 385/18723 | 4.41e-07 | 6.00e-06 | 224 |
| GO:0072521111 | Esophagus | ESCC | purine-containing compound metabolic process | 238/8552 | 416/18723 | 1.20e-06 | 1.49e-05 | 238 |
| GO:0009150111 | Esophagus | ESCC | purine ribonucleotide metabolic process | 213/8552 | 368/18723 | 1.40e-06 | 1.69e-05 | 213 |
| GO:0006163111 | Esophagus | ESCC | purine nucleotide metabolic process | 226/8552 | 396/18723 | 2.81e-06 | 3.21e-05 | 226 |
| GO:00060069 | Esophagus | ESCC | glucose metabolic process | 119/8552 | 196/18723 | 1.51e-05 | 1.36e-04 | 119 |
| GO:000913219 | Esophagus | ESCC | nucleoside diphosphate metabolic process | 77/8552 | 124/18723 | 1.65e-04 | 1.09e-03 | 77 |
| GO:000918520 | Esophagus | ESCC | ribonucleoside diphosphate metabolic process | 66/8552 | 106/18723 | 4.21e-04 | 2.39e-03 | 66 |
| GO:001605216 | Esophagus | ESCC | carbohydrate catabolic process | 91/8552 | 154/18723 | 5.39e-04 | 2.97e-03 | 91 |
| GO:000913520 | Esophagus | ESCC | purine nucleoside diphosphate metabolic process | 63/8552 | 103/18723 | 1.10e-03 | 5.52e-03 | 63 |
| GO:000917920 | Esophagus | ESCC | purine ribonucleoside diphosphate metabolic process | 63/8552 | 103/18723 | 1.10e-03 | 5.52e-03 | 63 |
| GO:004693919 | Esophagus | ESCC | nucleotide phosphorylation | 61/8552 | 101/18723 | 2.03e-03 | 9.08e-03 | 61 |
| GO:004603119 | Esophagus | ESCC | ADP metabolic process | 55/8552 | 90/18723 | 2.27e-03 | 9.99e-03 | 55 |
| GO:000609019 | Esophagus | ESCC | pyruvate metabolic process | 63/8552 | 106/18723 | 2.98e-03 | 1.24e-02 | 63 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0120023 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
| hsa0001016 | Esophagus | ESCC | Glycolysis / Gluconeogenesis | 42/4205 | 67/8465 | 2.15e-02 | 4.78e-02 | 2.45e-02 | 42 |
| hsa0120033 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
| hsa0001017 | Esophagus | ESCC | Glycolysis / Gluconeogenesis | 42/4205 | 67/8465 | 2.15e-02 | 4.78e-02 | 2.45e-02 | 42 |
| hsa0120041 | Liver | HCC | Carbon metabolism | 89/4020 | 115/8465 | 3.92e-11 | 6.56e-10 | 3.65e-10 | 89 |
| hsa0001022 | Liver | HCC | Glycolysis / Gluconeogenesis | 43/4020 | 67/8465 | 4.26e-03 | 1.29e-02 | 7.15e-03 | 43 |
| hsa0120051 | Liver | HCC | Carbon metabolism | 89/4020 | 115/8465 | 3.92e-11 | 6.56e-10 | 3.65e-10 | 89 |
| hsa0001032 | Liver | HCC | Glycolysis / Gluconeogenesis | 43/4020 | 67/8465 | 4.26e-03 | 1.29e-02 | 7.15e-03 | 43 |
| hsa0120014 | Oral cavity | OSCC | Carbon metabolism | 74/3704 | 115/8465 | 6.10e-06 | 3.05e-05 | 1.55e-05 | 74 |
| hsa0001014 | Oral cavity | OSCC | Glycolysis / Gluconeogenesis | 40/3704 | 67/8465 | 6.08e-03 | 1.44e-02 | 7.31e-03 | 40 |
| hsa0120015 | Oral cavity | OSCC | Carbon metabolism | 74/3704 | 115/8465 | 6.10e-06 | 3.05e-05 | 1.55e-05 | 74 |
| hsa0001015 | Oral cavity | OSCC | Glycolysis / Gluconeogenesis | 40/3704 | 67/8465 | 6.08e-03 | 1.44e-02 | 7.31e-03 | 40 |
| hsa0120022 | Oral cavity | LP | Carbon metabolism | 62/2418 | 115/8465 | 8.38e-09 | 1.39e-07 | 8.99e-08 | 62 |
| hsa0001023 | Oral cavity | LP | Glycolysis / Gluconeogenesis | 28/2418 | 67/8465 | 1.36e-02 | 4.44e-02 | 2.86e-02 | 28 |
| hsa0120032 | Oral cavity | LP | Carbon metabolism | 62/2418 | 115/8465 | 8.38e-09 | 1.39e-07 | 8.99e-08 | 62 |
| hsa0001033 | Oral cavity | LP | Glycolysis / Gluconeogenesis | 28/2418 | 67/8465 | 1.36e-02 | 4.44e-02 | 2.86e-02 | 28 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ADPGK | SNV | Missense_Mutation | novel | c.693N>A | p.Phe231Leu | p.F231L | Q9BRR6 | protein_coding | tolerated(0.23) | benign(0.023) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ADPGK | SNV | Missense_Mutation | c.364T>C | p.Phe122Leu | p.F122L | Q9BRR6 | protein_coding | deleterious(0.01) | benign(0.341) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ADPGK | SNV | Missense_Mutation | rs374477325 | c.700G>A | p.Asp234Asn | p.D234N | Q9BRR6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DF-A2KV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ADPGK | SNV | Missense_Mutation | novel | c.529N>T | p.Leu177Phe | p.L177F | Q9BRR6 | protein_coding | tolerated(0.1) | probably_damaging(0.929) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ADPGK | SNV | Missense_Mutation | novel | c.290N>A | p.Gly97Asp | p.G97D | Q9BRR6 | protein_coding | tolerated(0.18) | possibly_damaging(0.767) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ADPGK | SNV | Missense_Mutation | novel | c.916N>T | p.Leu306Phe | p.L306F | Q9BRR6 | protein_coding | tolerated(0.74) | benign(0.006) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ADPGK | insertion | Frame_Shift_Ins | novel | c.977_978insATCCT | p.Glu327SerfsTer38 | p.E327Sfs*38 | Q9BRR6 | protein_coding | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | ||
| ADPGK | SNV | Missense_Mutation | novel | c.745A>G | p.Ser249Gly | p.S249G | Q9BRR6 | protein_coding | deleterious(0.01) | possibly_damaging(0.74) | TCGA-95-7567-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD |
| ADPGK | SNV | Missense_Mutation | rs142833607 | c.782N>G | p.Ser261Cys | p.S261C | Q9BRR6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-CQ-5327-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| ADPGK | SNV | Missense_Mutation | novel | c.1367N>C | p.Arg456Thr | p.R456T | Q9BRR6 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-CV-7418-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |